A recent study from the Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; and Institute for Biomedical Research, University College London, London, UK shows that “Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation.” This study was published in the Apr 23 2014 Nature by Prof Ulrich H. von Andrian, Lorena Riol-Blanco, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Treating Psoriasis with an NIDDM drug: Acarbose, the widely used drug in the treatment of T2D, decreases psoriasiform skin inflammation via down regulation of its target gene. This study suggests that Acarbose, by increasing the expression of its target gene, it may alleviate the interleukin-23-mediated psoriasiform skin inflammation. Together, this study suggests that pharmacological formulations encompassing “Acarbose or its analogues” may be used to treat psoriasiform skin inflammation.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Treating Psoriasis with an NIDDM drug: Acarbose, the widely used drug in the treatment of T2D, decreases psoriasiform skin inflammation via down regulation of its target gene., 28/September/2014, 05.27 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation